Ultragenyx Pharmaceutical Inc. exited the Russell 1000 Index on June 28, 2026. Funds tracking the index must now sell their shares of the company. This mandatory liquidation is expected to create temporary selling pressure on the stock.
The removal follows a period of significant stock underperformance. Ultragenyx missed both earnings and revenue estimates in its first-quarter 2026 financial report.
The biopharmaceutical firm specializes in therapies for rare and ultrarare genetic diseases. This index exclusion adds a significant headwind to the company's current market position.